Advances in Therapy

, 24:963 | Cite as

Adverse effects of high-dose interferon-α-2a treatment for chronic hepatitis B

  • Elif Doyuk Kartal
  • Saygin Nayman Alpat
  • Ilhan Ozgunes
  • Gaye Usluer


The aim of this study was to assess morbidity and the incidence of adverse effects during interferon (IFN)-α-2a treatment of patients with chronic hepatitis B. This prospective study included 48 consecutive patients with chronic hepatitis B who underwent IFN-α-2a treatment from January 2003 to August 2005. Adverse effects related to IFN treatment were recorded during this period and for 6 mo after treatment. Adverse effects that led to dose reduction or early discontinuation of IFN treatment were examined. Complete response was reported in 25% of patients. At least 1 adverse effect was documented in 88% of patients. Flu-like symptoms were the most frequently observed adverse effects (88%), and thrombocytopenia (63%), leukopenia (54%), and anemia (23%) were also reported. Bleeding occurred in 2 patients. Other adverse effects included neuropsychiatric signs (21%), alopecia (19%), weight loss (17%), thyroid disorders (19%), menstrual cycle irregularities (8%), skin lesions (8%), and dry cough (4%). Adverse effects that led to dose reduction or early discontinuation of IFN treatment occurred in 19% of patients and included impotence, depression, seizure, thyroid disorders, severe thrombocytopenia, and intestinal bleeding. These effects were found to be unrelated to treatment response. No relationship was detected between patient age, duration of treatment, and adverse effects of IFN. Although IFN-α-2a treatment induced various adverse effects in patients with chronic hepatitis B, most of these effects were reversible or could be ameliorated. Adverse effects that led to dose reduction or early discontinuation of IFN treatment were found to be unrelated to complete response.


interferon-α-2a chronic hepatitis B adverse effects 


  1. 1.
    Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Liver Int. 2005;25:472–489.PubMedCrossRefGoogle Scholar
  2. 2.
    Buti M, Esteban R. Drugs in development for hepatitis B.Drugs. 2005;65:1451–1460.PubMedCrossRefGoogle Scholar
  3. 3.
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C.Hepatology. 2001;34:395–403.PubMedCrossRefGoogle Scholar
  4. 4.
    Maddrey WC. Safety of combination interferon alfa-2b/ribavirin treatment in chronic hepatitis C-relapsed and treatment-naive patients.Semin Liver Dis. 1999;19:67–75.PubMedGoogle Scholar
  5. 5.
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C.Hepatology. 1997;26:112–121.CrossRefGoogle Scholar
  6. 6.
    Fattovich G, Giustina G, Favarato S, Ruol A. A survey of side events in 11241 patients with chronic viral hepatitis treated with alfa interferon.J Hepatol. 1996;24:38–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Wai CT, Lok SF. Treatment of hepatitis B.J Gastroenterol. 2002;37:771–778.PubMedCrossRefGoogle Scholar
  8. 8.
    Kraus MR, Schafer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.World J Gastroenterol. 2005;11:1762–1774.Google Scholar
  9. 9.
    Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral treatment for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.Cleveland Clin J Med. 2004;71:17–21.CrossRefGoogle Scholar
  10. 10.
    Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.Lur J Endocrinol. 1995; 132:587–593.CrossRefGoogle Scholar
  11. 11.
    Fried MW. Side effects of treatment of hepatitis C and their management.Hepatology. 2002; 36:237–244.CrossRefGoogle Scholar
  12. 12.
    Cadoni G, Marinelli L, De Santis A, Romito A, Mana R, Ottavianni F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis.J Laryngol Otol. 1998;112:962–963.PubMedCrossRefGoogle Scholar
  13. 13.
    Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.Am J Med Sci. 2001;22:233–235.CrossRefGoogle Scholar
  14. 14.
    Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Side effects of interferon on the cardiovascular system in patients with chronic hepatitis C.Jpn Heart J. 1996;37:905–915.PubMedGoogle Scholar
  15. 15.
    Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high dose interferon treatment for chronic hepatitis C.J Hepatol. 1996;25:283–291.PubMedCrossRefGoogle Scholar
  16. 16.
    Dormann H, Krebs S, Muth-Selbach U, et al. Rapid onset of hematotoxic effects after interferon alpha in hepatitis C.J Hepatol. 2000;32:1041–1042.PubMedCrossRefGoogle Scholar
  17. 17.
    Renou C, Harafa A, Bouabdallah R, et al. Severe neutropenia and post-hepatitis C cirrhosis treatment: is Interferon dose adaptation at once necessary?Am J Gastroenterol. 2002;97:1260–1262.PubMedCrossRefGoogle Scholar
  18. 18.
    Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease.Thyroid. 2003;13:547–551.PubMedCrossRefGoogle Scholar
  19. 19.
    Fontaine H, Pol S. Side effect of interferon-α in treating hepatitis C virus infection.Transplant Proc. 2001;33:2327–2329.PubMedCrossRefGoogle Scholar
  20. 20.
    Wong V, Xi-Li Fu A, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon treatment in chronic viral hepatitis.Clin Endocrinol. 2002;56:793–798.CrossRefGoogle Scholar
  21. 21.
    Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C.J Hepatol. 1999;30:794–800.PubMedCrossRefGoogle Scholar
  22. 22.
    Gupta G, Holmes SC, Spence E, Mills P. Capillaritis associated with interferon-alfa treatment of chronic hepatitis C infection.J Am Acad Dermatol.2000;43:937–938.PubMedCrossRefGoogle Scholar
  23. 23.
    Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-α.Br J Dermatol. 1991;125:463–465.PubMedCrossRefGoogle Scholar
  24. 24.
    Kelkar PS, Kalaaji AN. Urticarial vasculitis with asymptomatic chronic hepatitis infection: response to doxepin, interferon-alfa, and ribavirin.J Clin Gastroenterol. 2002;35:281–282.PubMedCrossRefGoogle Scholar
  25. 25.
    Aspinall RJ, Pockros PJ. The management of side-effects during treatment for hepatitis C.Aliment Pharmacol Ther. 2004;20:917–929.PubMedCrossRefGoogle Scholar
  26. 26.
    Gutierrez G, Pereda A. Granulocyte colony stimulating factor for the treatment of interferoninduced neutropenia in patients with chronic hepatitis B.J Pediatr Gastroenterol Nutr. 2001; 32:225.PubMedGoogle Scholar
  27. 27.
    Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α.Am J Gastroenterol. 2001;96:2802–2803.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2007

Authors and Affiliations

  • Elif Doyuk Kartal
    • 1
  • Saygin Nayman Alpat
    • 1
  • Ilhan Ozgunes
    • 1
  • Gaye Usluer
    • 1
  1. 1.Department of Infectious Diseases and Clinical BacteriologyEskisehir Osmangazi University Medical FacultyEskisehirTurkey

Personalised recommendations